Glass House Brands Triggers Warrant Acceleration

LONG BEACH – Glass House Brands Inc., a major player in California Cannabis production and retail, has told holders of warrants issued in two earlier financing rounds that their right to convert those securities into shares will end well ahead of schedule. The company said the early cutoff was set in motion after its stock sustained a price run above a ceiling written into the warrant agreements.

In a notice released yesterday, Glass House said it had exercised acceleration rights tied to warrant indentures dated August 2022 and August 2023, covering its Series B, C, and D Warrants. Under those agreements, the company can shorten the warrants’ remaining life once its shares close at or above $12.00 for ten trading days within any fifteen-day trading window. That level equals 240% of the exercise price on the Series B and C Warrants and 200% of the exercise price on the Series D Warrants.

Glass House confirmed that its shares met that condition by the close of trading on June 18, prompting the company to deliver formal notice to Odyssey Trust Company, the warrant agent, along with registered holders.

The notice follows other recent activity at GHB. The company recently deconsolidated its dual-use retail business from its medical Cannabis operations and applied to list its subordinate voting shares on the New York Stock Exchange, a step tied to its push for broader access to U.S. capital markets. It also established an at-the-market equity program permitting sales of up to $100 million in shares, proceeds it has said will go toward cultivation expansion and possible acquisitions.

Shares of Glass House have traded near their 52-week high in recent weeks, alongside renewed investor interest in U.S. Cannabis companies positioning for federal rescheduling and wider exchange access. The notice compresses the timeline for holders who might otherwise have waited far longer to decide.

Acceleration clauses exist for a simple reason. They let issuers clear equity overhangs once a share price has shown it can hold above a set level. For GHB, forcing an early decision on a meaningful slate of warrants reduces the share count that would otherwise sit on the books for years and removes a layer of uncertainty for anyone modeling fully diluted valuation. The timing, set against the NYSE application and the new at-the-market program, points to a management team tightening its capital structure before it competes for attention from a wider pool of U.S. institutional investors.

What happens with exercise rates over the coming weeks will say less about Glass House’s underlying Cannabis operations and more about how comfortable holders are locking in gains at current trading levels.